Amgen (NASDAQ:AMGN) Announces Quarterly Earnings Results

Amgen (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27, Zacks reports. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen updated its FY 2025 guidance to 20.000-21.200 EPS.

Amgen Trading Up 6.5 %

NASDAQ:AMGN opened at $307.81 on Thursday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen has a one year low of $253.30 and a one year high of $346.85. The company has a market cap of $165.46 billion, a PE ratio of 39.41, a PEG ratio of 2.87 and a beta of 0.56. The firm has a 50-day moving average of $271.69 and a 200-day moving average of $303.55.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.09%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 115.24%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AMGN shares. Wolfe Research assumed coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Bank of America boosted their price objective on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a research note on Thursday. Truist Financial lowered their target price on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Leerink Partners reduced their price target on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Wells Fargo & Company lowered their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research report on Friday, January 10th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $314.83.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.